Clinical Trial Update: Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ipilimumab in metastatic or recurrent HPV-related cervical cancer has completed; results were posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Adenocarcinoma
• Cervical Cancer
• Cervical Squamous Cell Carcinoma

Drugs mentioned

• ipilimumab (ipilimumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2022-11-08